ORKA
Oruka TherapeuticsยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ORKA
Oruka Therapeutics, Inc.
A biotechnology company focused on developing innovative drugs for the treatment of chronic skin diseases
855 Oak Grove Avenue, Suite 100, Menlo Park, California, 94025
--
Oruka Therapeutics, Inc. Completed the Business Combination (Merger) with ARCA Colorado under the terms of the Agreement and Plan of Merger and Reorganization dated September 24, 2008, as amended on October 28, 2008, wherein a wholly-owned subsidiary of Nuvelo, Inc., merged with ARCA Colorado, ARCA Colorado continues as the surviving company and a wholly-owned subsidiary of Nuvelo, Inc. Immediately following the merger, the company changed its name from Nuvelo, Inc. to ARCA Biopharma, Inc. Nuvelo was originally incorporated as HYSEQ. The company is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapies for psoriasis, inflammation and immunological indications.
Company Financials
EPS
ORKA has released its 2025 Q3 earnings. EPS was reported at -0.55, versus the expected -0.52, missing expectations. The chart below visualizes how ORKA has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
